Drug Profile
Etripamil - Milestone Pharmaceuticals
Alternative Names: (-)-MSP-2017; CARDAMYST; MSP-2017; MSP-2017A; MSP-2017BLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Milestone Pharmaceuticals
- Developer Ji Xing Pharmaceuticals; Milestone Pharmaceuticals
- Class Amines; Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Paroxysmal supraventricular tachycardia
- Phase II Atrial fibrillation
- Phase I Unspecified
- No development reported Angina pectoris
Most Recent Events
- 21 Mar 2024 Milestone Pharmaceuticals that announces end of phase II meeting expected mid-2024 for atrial fibrillation
- 26 Feb 2024 Milestone Pharmaceuticals plans to resubmit New Drug Application (NDA) to the US FDA for Paroxysmal supraventricular tachycardia in the second quarter of 2024
- 28 Dec 2023 Milestone Pharmaceuticals receives a refusal to file (RTF) letter from the US FDA for new drug application (NDA) for Etripamil in Paroxysmal supraventricular tachycardia (PSVT)